Boston Scientific Secures FDA Approval To Expand Indication For Current-generation INGEVITY+ Pacing Leads To Include Conduction System Pacing Of Left Bundle Branch Area
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has received FDA approval to expand the indication for its INGEVITY+ pacing leads to include conduction system pacing of the left bundle branch area. This approval could enhance the company's market position in cardiac pacing solutions.
September 17, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Boston Scientific received FDA approval to expand the use of its INGEVITY+ pacing leads, which could strengthen its market position in cardiac pacing solutions.
The FDA approval allows Boston Scientific to expand the use of its INGEVITY+ pacing leads, which could lead to increased adoption and sales in the cardiac pacing market. This regulatory milestone is likely to positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100